Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens

Journal of Clinical Microbiology

Volumn 47, Issue 12, 2009, Pages 3797-3804

  Pfaller, M A ^a   Messer, S A ^a   Georgopapadakou, N ^b   Martell, L A ^b   Besterman, J M ^b   Diekema, D J ^a  

^a UNIVERSITY OF IOWA   (United States)

^b METHYLGENE INC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; HISTONE DEACETYLASE INHIBITOR; MGCD 290; POSACONAZOLE; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS; CANDIDA; CRYPTOCOCCUS NEOFORMANS; DRUG POTENTIATION; FUSARIUM; MINIMUM INHIBITORY CONCENTRATION; MOULD; MUCOR; MYCOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RHIZOPUS; RHODOTORULA; SCEDOSPORIUM; TRICHOSPORON; ZYGOMYCETES;

ANTIFUNGAL AGENTS; DRUG RESISTANCE, FUNGAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FUNGI; HISTONE DEACETYLASE INHIBITORS; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES; OPPORTUNISTIC INFECTIONS; TRIAZOLES;

ASPERGILLUS; CANDIDA; FILOBASIDIELLA NEOFORMANS; FUSARIUM; MUCOR; RHIZOPUS; SCEDOSPORIUM; ZYGOMYCETES;

EID: 71549146873     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00618-09     Document Type: Article

References (36)

1. Akache, B., et al. 2007. Abstr. 107th Gen. Meet. Am. Soc. Microbiol., abstr. A-093.
2. Andrews, K. T., T. N. Tran, A. J. Lucke, P. Kahnberg, G. T. Lee, G. M. Boyle, D. L. Gardiner, T. S. Skinner-Adams, and D. P. Fairlie. 2008. Potent antimalarial activity of histone deacetylase inhibitor analogues. Antimicrob. Agents Chemother. 52:1454-1461.
3. Chaturvedi, V., R. Ramani, M. A. Ghannoum, S. B. Killian, N. Holliday, C. Knapp, L. Ostrosky-Zeichner, S. A. Messer, M. A. Pfaller, N. J. Igbal, B. A. Arthington-Skaggs, J. A. Vazquez, T. Sein, J. H. Rex, and T. J. Walsh. 2008. Multilaboratory testing of antifungal combinations against a quality control isolate of Candida krusei. Antimicrob. Agents Chemother. 52:1500-1502.
4. Chen, A., and J. D. Sobel. 2005. Emerging azole antifungals. Expert Opin. Emerg. Drugs 10:21-33.
5. Clinical and Laboratory Standards Institute. 2007. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 3rd ed., M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Clinical and Laboratory Standards Institute. 2007. Reference method for broth dilution antifungal susceptibility testing of yeasts: informational supplement, M27-S3. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd ed., M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Colletti, S. L., R. W. Myers, S. J. Darkin-Rattray, A. M. Gurnett, P. M. Dulski, S. Faluska, J. J. Allocco, M. B. Ayer, C. Li, J. Lim, T. M. Crumley, C. Cannova, D. M. Schmatz, M. J. Wyvratt, M. H. Fisher, and P. T. Meinke. 2001. Broad-spectrum antiprotozoal agents that inhibit histone deacetylase: structure-activity relationships of apicidin. Part 1. Bioorg. Med. Chem. Lett. 11:107-111.
9. Cuenca-Estrella, M. 2004. Combinations of antifungal agents in therapy - what value are they? J. Antimicrob. Chemother. 54:854-869.
10. Diekema, D. J., et al. 2007. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., abstr. M-1822.
11. Grozinger, C. M., and S. L. Schreiber. 2002. Deactylase enzymes: biological functions and the use of small-molecule inhibitors. Chem. Biol. 9:3-16.
12. Grunstein, M. 1997. Histone acetylation in chromatin structure and transcription. Nature 389:349-352. (Pubitemid 27415209)
13. Hof, H. 2008. Will resistance in fungi emerge on a scale similar to that seen in bacteria? Eur. J. Clin. Microbiol. Infect. Dis. 27:327-334.
14. Johnson, M. D., C. MacDougall, L. Ostrosky-Zeichner, J. R. Perfect, and J. H. Rex. 2004. Combination antifungal therapy. Antimicrob. Agents Chemother. 48:693-715.
15. Kim, J. H., N. Mahoney, K. L. Chon, R. J. Molyneux, G. S. May, and B. C. Campbell. 2008. Chemosensitization of fungal pathogens to antimicrobial agents using benzo analogs. FEMS Microbiol. Lett. 281:64-72.
16. Larone, D. H. 2002. Medically important fungi: a guide to identification, 4th ed. ASM Press, Washington, DC.
17. Li, Y., S. Sun, Q. Guo, L. Ma, C. Shi, L. Su, and H. Li. 2008. In vitro interaction between azoles and cyclosporine A against clinical isolates of Candida albicans determined by the chequerboard method and time-kill curves. J. Antimicrob. Chemother. 61:577-585.
18. Maertens, J. A. 2004. History of the development of azole derivatives. Clin. Microbiol. Infect. 10(Suppl. 1):1-10.
19. Mai, A., D. Rotili, S. Massa, G. Brosch, G. Simnonetti, C. Passariello, and A. T. Palamara. 2007. Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans. Bioorg. Med. Chem. Lett. 17:1221-1225. (Pubitemid 46240856)
20. Matthews, R. C., G. Riggs, S. Hodgetts, T. Carter, C. Chapman, C. Gregory, C. Illidge, and J. Burnie. 2003. Preclinical assessment of the efficacy of Mycograb, a human recombinant antibody against fungal HSP90. Antimicrob. Agents Chemother. 47:2208-2216.
21. McElhaney-Feser, G. E., R. Raulli, and R. L. Cihlar. 1998. Synergy of nitric oxide and azoles against Candida species in vitro. Antimicrob. Agents Chemother. 42:2342-2346.
22. Metcalf, S. C., and D. H. Dockrell. 2007. Improved outcomes associated with advance in therapy for invasive fungal infections in immunocompromised hosts. J. Infect. 55:287-299.
23. Moody, J. A. 1991. Synergism testing. Broth microdilution checkerboard and broth macrodilution methods, p. 5.18.1-5.18.28. In H. D. Isenberg (ed.), Clinical microbiology procedures handbook, vol.1 American Society for Microbiology, Washington, DC.
24. Moradei, O., C. R. Maroun, I. Paquin, and A. Vaisburg. 2005. Histone deacetylase inhibitors: latest developments, trends and prospects. Curr. Med. Chem. Anticancer Agents 5:529-560.
25. Nooney, L., R. C. Matthews, and J. P. Burnie. 2005. Evaluation of Mycograb®, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies. Diagn. Microbiol. Infect. Dis. 51:19-29.
26. Pappas, P. G., J. H. Rex, J. D. Sobel, S. G. Filler, W. E. Dismukes, T. J. Walsh, and J. E. Edwards for the Infectious Diseases Society of America. 2004. Guidelines for treatment of candidiasis. Clin. Infect. Dis. 38:161-189.
27. Pfaller, M. A., and D. J. Diekema. 2007. Azole antifungal drug cross-resistance: mechanisms, epidemiology, and clinical significance. J. Invasive Fungal Infect. 1:74-92.
28. Richon, V. M., and J. P. O'Brien. 2002. Histone deacteylase inhibitors: a new class of potential therapeutic agents for cancer treatment. Clin. Cancer Res. 8:662-664.
29. Sangland, D., and F. C. Odds. 2002. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect. Dis. 2:73-85.
30. Shao, P. L., L. M. Huong, and P. R. Hsueh. 2007. Recent advances and challenges in the treatment of invasive fungal infections. Int. J. Antimicrob. Agents 30:487-495.
31. Smith, W. L., and T. D. Edlind. 2002. Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals: correlation with reduction in CDR and ERG upregulation. Antimicrob. Agents Chemother. 46:3532-3539.
32. Spanakis, E. K., G. Aperis, and E. Mylonakis. 2006. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin. Infect. Dis. 43:1060-1068.
33. Spellberg, B. J., S. G. Filler, and J. E. Edwards, Jr. 2006. Current treatment strategies for disseminated candidiasis. Clin. Infect. Dis. 42:244-251.
34. Sterner, D. E., and S. L. Berger. 2000. Acetylation of histones and transcription-related factors. Microbiol. Mol. Biol. Rev. 64:435-459.
35. Walsh, T. J., E. J. Anaissie, D. W. Denning, R. Herbrecht, D. P. Kontoyiannis, K. A. Marr, V. A. Morrison, B. H. Segal, W. J. Steinbach, D. A. Stevens, J. A. van Burik, J. R. Wingard, and T. F. Patterson. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360.
36. White, T. C. 2007. Mechanisms of resistance to antifungal agents, p. 1961-1971. In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. L. Landry, and M. A. Pfaller (ed.), Manual of clinical microbiology, 9th ed., ASM Press, Washington, DC.